Compare VRTX to:
After Hours: 0.00 N/A (N/A) 7:00pm ET
| Last Trade: | 37.90 |
|---|---|
| Trade Time: | Feb 9 |
| Change: | 0.00 (0.00%) |
| Prev Close: | 37.90 |
| Open: | N/A |
| Bid: | N/A |
| Ask: | 41.75 x 100 |
| 1y Target Est: | 44.30 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 25.94 - 44.24 |
| Volume: | 0 |
| Avg Vol (3m): | 2,008,970 |
| Market Cap: | 6.87B |
| P/E (ttm): | N/A |
| EPS (ttm): | -3.82 |
| Div & Yield: | N/A (N/A) |
| Sat, Feb 6 | New Star Analyst Rankings for Vertex Pharmaceuticals IncorporStarMine |
| Fri, Feb 5 | Vertex Pharmaceuticals Inc. Q4 2009 Earnings Call Transcriptat Seeking Alpha |
| Thu, Feb 4 | [video] Successfactors, Pitney Bowes Announceat Forbes.com |
| Thu, Feb 4 | UPDATE - Vertex 4th quarter loss grows with costsat Reuters |
| Thu, Feb 4 | VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemenEDGAR Online |
| Thu, Feb 4 | Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development ProgramsBusiness Wire |
| Thu, Feb 4 | Full Year 2009 Vertex Pharmaceuticals Incorporated Earnings Release - After Market CloseCCBN |
| Wed, Feb 3 | Vertex sees positive data in cystic fibrosis studyAP |
| Wed, Feb 3 | UPDATE - Vertex cystic fibrosis drug shows promise in trialat Reuters |
| Wed, Feb 3 | Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic FibrosisBusiness Wire |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.